Biocryst Pharmaceuticals (BCRX) Retained Earnings (2010 - 2026)

Biocryst Pharmaceuticals has reported Retained Earnings for 17 years, with the latest figure at -$2.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 196918.99% year-over-year to -$2.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.2 billion (down 196918.99% YoY), and the FY2025 full-year result was $38000.0, up 100.0% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.2 billion, down from $38000.0 in the prior quarter.
• The five-year high for Retained Earnings was $1.1 million in Q3 2025, with the low at -$2.2 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$888.5 million across 5 years, with a median of -$1.3 billion in 2022.
• The largest YoY upside for Retained Earnings was 916.33% in 2023 against a maximum downside of 6466096.15% in 2023.
• Biocryst Pharmaceuticals' Retained Earnings stood at $26000.0 in 2022, then slumped by 6466096.15% to -$1.7 billion in 2023, then declined by 5.29% to -$1.8 billion in 2024, then surged by 100.0% to $38000.0 in 2025, then tumbled by 5863234.21% to -$2.2 billion in 2026.
• The last three Retained Earnings figures came in at -$2.2 billion (Q1 2026), $38000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.